Text size :

Rhinosinusitis with nasal polyps, Italian study confirms the efficacy of mepolizumab

ADNKRONOS

November 16, 2026

Rome, Nov 16. (Adnkronos Health) – New evidence from Italian research on the management of severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), a chronic inflammatory disease that can significantly impair people’s quality of life, causing persistent nasal obstruction, loss of smell, sleep disturbances, and difficulties in daily activities. This evidence is provided by Meporeal, an Italian real-world phase 4 study, published in ‘The Lancet Respiratory Medicine’, which evaluated the efficacy and safety of mepolizumab in patients with this condition in daily clinical practice.

The research – a note informs – involved 621 patients followed in 25 Italian specialist centers, representing one of the largest real-world multicenter experiences on the use of mepolizumab. After 12 months of treatment, Meporeal documented significant improvements in key clinical parameters and patients’ quality of life. The median score of the endoscopic nasal polyp severity index, which measures the extent of polyposis, halved, decreasing from 6 to 3. In parallel, the Snot-22 score, used to assess the impact of the disease on quality of life, decreased from a median of 59 to 21 points. A significant result concerns the achievement of broader therapeutic goals: 42% of patients achieved disease control, while approximately 20% met the clinical criteria for clinical remission under treatment without yet having completed the observation period necessary to formally confirm it. The results take on particular significance considering the complexity of the population involved. More than half of the patients (52%) had concomitant asthma, and many had already undergone one or more surgical interventions for nasal polyposis. Improvements also affected the main symptoms and olfactory function.

“The value of Meporeal lies in having brought research directly into daily clinical practice, gathering the experience of 25 Italian centers and over 600 patients with severe and uncontrolled CRSwNP. The results offer us new evidence on the improvement of symptoms and quality of life, but also set more ambitious therapeutic goals, such as disease control and the path towards clinical remission under treatment. It is an important contribution to better understand how to manage this condition in the long term and demonstrates the value of collaboration between specialist centers in producing scientific evidence useful for clinical practice,” states Eugenio De Corso, professor at the University of Perugia, Department of Medicine and Surgery, Otorhinolaryngology section, Santa Maria della Misericordia Hospital, Perugia.

Jiji Press

Related

Page TOP